AbbVie Inc. $ABBV Holdings Decreased by Legal & General Group Plc

Legal & General Group Plc trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 1.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,510,664 shares of the company’s stock after selling 171,264 shares during the period. AbbVie comprises approximately 0.5% of Legal & General Group Plc’s investment portfolio, making the stock its 23rd biggest position. Legal & General Group Plc’s holdings in AbbVie were worth $2,136,609,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in ABBV. MAI Capital Management boosted its position in shares of AbbVie by 3.8% in the second quarter. MAI Capital Management now owns 539,434 shares of the company’s stock valued at $100,130,000 after acquiring an additional 19,996 shares during the period. Hillsdale Investment Management Inc. lifted its stake in AbbVie by 954.3% in the second quarter. Hillsdale Investment Management Inc. now owns 18,008 shares of the company’s stock valued at $3,343,000 after buying an additional 16,300 shares during the period. Ames National Corp bought a new position in AbbVie in the second quarter valued at approximately $272,000. YANKCOM Partnership increased its position in shares of AbbVie by 2.4% in the second quarter. YANKCOM Partnership now owns 9,766 shares of the company’s stock valued at $1,813,000 after acquiring an additional 227 shares during the last quarter. Finally, DNB Asset Management AS grew its holdings in AbbVie by 7.3% during the second quarter. DNB Asset Management AS now owns 503,046 shares of the company’s stock worth $93,375,000 after purchasing an additional 34,096 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Down 1.4%

Shares of ABBV opened at $229.75 on Friday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company’s fifty day moving average is $226.46 and its 200 day moving average is $204.95. The stock has a market capitalization of $406.06 billion, a PE ratio of 109.41, a P/E/G ratio of 1.42 and a beta of 0.50.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analyst Ratings Changes

ABBV has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Hsbc Global Res lowered AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, HSBC set a $225.00 target price on AbbVie in a research note on Thursday, October 2nd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $240.14.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.